Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.99 USD | -3.76% | -4.20% | +20.84% |
Sales 2024 * | 27.24M 34.71M | Sales 2025 * | 32.04M 40.82M | Capitalization | 769M 980M |
---|---|---|---|---|---|
Net income 2024 * | -40M -50.96M | Net income 2025 * | -73M -93.01M | EV / Sales 2024 * | 24.9 x |
Net cash position 2024 * | 91.87M 117M | Net cash position 2025 * | 84.26M 107M | EV / Sales 2025 * | 21.4 x |
P/E ratio 2024 * |
-53.9
x | P/E ratio 2025 * |
-31.4
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Silence Therapeutics plc
1 day | -3.76% | ||
1 week | -4.20% | ||
1 month | -3.98% | ||
3 months | -17.59% | ||
6 months | +63.09% | ||
Current year | +20.84% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Tooman
CEO | Chief Executive Officer | 58 | 21-01-05 |
Director of Finance/CFO | 52 | 21-03-31 | |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Romano
CTO | Chief Tech/Sci/R&D Officer | 64 | 19-07-28 |
David Lemus
BRD | Director/Board Member | 61 | 18-06-20 |
Iain Ross
CHM | Chairman | 71 | 04-07-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 20.99 | -3.76% | 62,455 |
24-05-30 | 21.81 | +1.25% | 31,774 |
24-05-29 | 21.54 | -2.49% | 43,056 |
24-05-28 | 22.09 | +0.82% | 66,954 |
24-05-24 | 21.91 | -0.41% | 43,820 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
- Stock Market
- Equities
- SLN Stock